Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 8/20 | 1.00 |
| ▸ | SHBG | P04278 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cortodoxone SCHEMBL16834876 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL3641463 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL1592553 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL13352414 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL42590 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL1592718 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL24900239 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL17906542 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL13768127 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| SCHEMBL6019058 | 0.91 | HSD17B10 (0.84) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712443-B2 | 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors | COSMO TECHNOLOGIES LIMITED (IE) | 2023-08-01 | — | — | US | disclosed |
| US-11712443-B2 | 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors | COSMO TECHNOLOGIES LIMITED (IE) | 2023-08-01 | — | — | US | disclosed |
| US-20230128438-A1 | 17A-MONOESTERS AND 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | COSMO TECHNOLOGIES LTD. (IE) | 2023-04-27 | — | — | US | disclosed |
| US-20230128438-A1 | 17A-MONOESTERS AND 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | COSMO TECHNOLOGIES LTD. (IE) | 2023-04-27 | — | — | US | disclosed |
| US-20220324901-A1 | PROCESS FOR THE PREPARATION OF CORTEXOLONE 17alpha-PROPIONATE AND NEW HYDRATED CRYSTALLINE FORM THEREOF | FARMABIOS S.P.A. (IT) | 2022-10-13 | — | — | US | disclosed |
| EP-4071160-A1 | PROCESS FOR THE PREPARATION OF CORTEXOLONE 17 A-PROPIONATE AND NEW HYDRATED CRYSTALLINE FORM THEREOF | Farmabios S.p.A. (IT) | 2022-10-12 | — | — | EP | disclosed |
| US-20210299145-A1 | 17A-MONOESTERS AND 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | COSMO TECHNOLOGIES LTD. (IE) | 2021-09-30 | — | — | US | disclosed |
| EP-3456330-B1 | CORTEXOLONE 17ALPHA-VALERATE FOR USE IN THE TREATMENT OF TUMOURS | COSMO TECHNOLOGIES LTD (IE) | 2021-05-19 | — | — | EP | disclosed |
| US-10993949-B2 | 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors | COSMO TECHNOLOGIES LIMITED (IE) | 2021-05-04 | — | — | US | disclosed |
| US-20200215080-A1 | 17A-MONOESTERS AND 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | COSMO TECHNOLOGIES LTD. (IE) | 2020-07-09 | — | — | US | disclosed |
| US-9638703-B2 | Quantification of glucocorticoids in fish scales as biomarkers for chronic stress | UNIVERSITEIT GENT (BE) | 2017-05-02 | — | — | US | disclosed |
| US-20160313355-A1 | QUANTIFICATION OF GLUCOCORTICOIDS IN FISH SCALES AS BIOMARKERS FOR CHRONIC STRESS | UNIVERSITEIT GENT (BE) | 2016-10-27 | — | — | US | disclosed |
| US-20160313355-A1 | QUANTIFICATION OF GLUCOCORTICOIDS IN FISH SCALES AS BIOMARKERS FOR CHRONIC STRESS | UNIVERSITEIT GENT (BE) | 2016-10-27 | — | — | US | disclosed |
| US-9394290-B2 | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases | UNIVERSITAET DES SAARLANDES CAMPUS SAARBRUECKEN (DE) | 2016-07-19 | — | — | US | disclosed |
| WO-2016055533-A1 | 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | COSMO TECHNOLOGIES LTD (IE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055537-A1 | CORTEXOLONE 17ALPHA-BENZOATE FOR USE IN THE TREATMENT OF TUMOURS | COSMO TECHNOLOGIES LTD (IE) | 2016-04-14 | — | — | WO | disclosed |
| EP-3006453-A1 | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors | Cosmo Technologies Ltd. (IE) | 2016-04-13 | — | — | EP | disclosed |
| US-20140155407-A1 | SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES | UNIVERSITAET DES SAARLANDES (DE) | 2014-06-05 | — | — | US | disclosed |
| US-20070259837-A1 | Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-08 | — | — | US | disclosed |
| US-20070259837-A1 | Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200215080-A1 | 17A-MONOESTERS AND 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | CYP17A1, CYP11B1, CYP19A1 | HSD17B10 181/4885SHBG 267/4885SMN1; SMN2 3553/4885 |
| US-11712443-B2 | 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors | CYP17A1, CYP11B1, CYP19A1 | HSD17B10 181/4885SHBG 271/4885SMN1; SMN2 3323/4885 |
| US-20220324901-A1 | PROCESS FOR THE PREPARATION OF CORTEXOLONE 17alpha-PROPIONATE AND NEW HYDRATED CRYSTALLINE FORM THEREOF | CYP17A1, HSD17B7, CYP21A2 | HSD17B10 42/4885SHBG 92/4885SMN1; SMN2 4868/4885 |
| US-20070259837-A1 | Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy | UTRN, MTPN, NR3C1 | HSD17B10 319/4885SHBG 87/4885SMN1; SMN2 100/4885 |
| US-20210299145-A1 | 17A-MONOESTERS AND 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | CYP17A1, CYP11B1, CYP19A1 | HSD17B10 181/4885SHBG 267/4885SMN1; SMN2 3553/4885 |
| US-20230128438-A1 | 17A-MONOESTERS AND 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | CYP17A1, CYP11B1, CYP19A1 | HSD17B10 181/4885SHBG 267/4885SMN1; SMN2 3553/4885 |
| US-10993949-B2 | 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors | CYP17A1, CYP11B1, CYP19A1 | HSD17B10 181/4885SHBG 271/4885SMN1; SMN2 3323/4885 |
| US-20140155407-A1 | SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES | HSD11B1, CYP11B1, HSD11B2 | HSD17B10 27/4885SHBG 59/4885SMN1; SMN2 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.